Cerevance

Cerevance is a clinical-stage biopharmaceutical company focused on developing precision novel therapeutics for central nervous system (CNS) diseases. They are committed to improving the lives of patients suffering from chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS). Cerevance's proprietary technology platform, Nuclear Enriched Transcript Sort sequencing (NETSseq), allows them to identify and target specific gene expression profiles in various brain cell types, leading to the development of innovative treatments.

Cerevance leverages a vast repository of over 15,000 human brain tissue samples to generate an unprecedented amount of expression and epigenetic data, enabling them to identify highly selective and novel targets for CNS disorders. Their robust pipeline consists of multiple therapeutic programs that are progressing through clinical development, with CVN424, CVN766, and CVN293 being their most advanced candidates. They are committed to transforming the lives of patients affected by CNS diseases through their groundbreaking research and clinical advancements.

Cerevance is a pharmaceutical company revolutionizing the treatment of central nervous system (CNS) disorders, particularly chronic neurodegenerative conditions like Alzheimer's, Parkinson's, and ALS. They utilize a proprietary platform called NETSseq, which analyzes gene expression profiles in select cell types within the brain to identify novel therapeutic targets that are uniquely expressed in relevant circuits affected by diseases or are altered in disease states. This data, combined with the expertise of their scientific team, allows them to develop precision neuroscience therapeutics that selectively modulate these targets, aiming to transform the lives of patients affected by CNS diseases.

Cerevance fosters a collaborative and innovative culture driven by a shared passion for developing precision therapeutics for central nervous system diseases. The company values teamwork, scientific excellence, and a commitment to improving the lives of patients. They prioritize a diverse and inclusive environment, recognizing the strength in perspectives from individuals with diverse backgrounds and experiences. Cerevance's team of world-leading scientists and drug developers are driven by a shared desire to transform the lives of those affected by CNS disorders.